fluticasone furoate/umeclidinium/vilanterol vs Umeclidinium/Vilanterol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanisms: Muscarinic acetylcholine receptor (M3) · Beta-2 adrenergic receptor · full Chronic Obstructive Pulmonary Disease pipeline
fluticasone furoate/umeclidinium/vilanterol · Trelegy Ellipta
Marketed by GlaxoSmithKline
NCT02164513 · Phase 3 · completed
This was a large randomized, double-blind, active-controlled trial in 10,355 COPD patients at 971 sites in 37 countries; the primary endpoint, annual on-treatment moderate/severe exacerbation rate, is a hard clinical outcome, and triple therapy significantly reduced exacerbations versus both dual-therapy comparators (rate ratio 0.75 vs UMEC/VI and 0.85 vs FF/VI, both p<0.001).
Next expected readout: September 2027 · NCT07192016 (registry estimate)
Reported efficacy
Annual Rate of On-treatment Moderate/Severe Exacerbations Comparing FF/UMEC/VI With UMEC/VI and FF/VI (Up to Week 52): Annual rate of on-treatment moderate/severe exacerbations: FF/UMEC/VI 0.91/yr vs FF/VI 1.07/yr (rate ratio 0.85, 95% CI 0.80-0.90, 15% reduction, p<0.001) vs UMEC/VI 1.21/yr (rate ratio 0.75, 95% CI 0.70-0.81, 25% reduction, p<0.001) (met)
Result source: NCT02164513
Umeclidinium/Vilanterol
Marketed by GlaxoSmithKline and partners
NCT01777334 · Phase 3 · completed
The trial randomly assigned 905 participants and used double blinding with tiotropium as an active comparator. Its primary endpoint was the clinical lung-function measure trough FEV1, and the primary comparison significantly favored umeclidinium/vilanterol.
Reported efficacy
Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24) (Baseline and Day 169): Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24) (Baseline and Day 169): UMEC/VI 62.5/25 µg 0.205 Liters (Standard Error 0.0114) vs TIO 18 µg 0.093 Liters (Standard Error 0.0115) (met)
Result source: NCT01777334
Results for Chronic Obstructive Pulmonary Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | fluticasone furoate/umeclidinium/vilanterol | Umeclidinium/Vilanterol |
|---|---|---|
| Moderate or severe exacerbations, annualised rate | 0.9 vs 1.1vs FF/VINCT021645132 other results
| —Trial running · NCT06474039 |
| Trough FEV1, change | 0.1 vs -0.0vs BUD/FORNCT0234516114 other results
| 0.2 vs 0.1vs TIONCT017773343 other results
|
| SGRQ total, change | -6.6 vs -4.3vs BUD/FORNCT023451613 other results
| —Trial running · NCT06474039 |
| TDI focal score | 2.3 vs 1.7vs BUD/FORNCT023451611 other result
| —Trial running · NCT06474039 |
Moderate or severe exacerbations, annualised rate
- fluticasone furoate/umeclidinium/vilanterol
- 0.9 vs 1.1vs FF/VINCT02164513
2 other results
- 0.2 vs 0.3 NCT02345161
- 0.2 vs 0.4 NCT02345161
- Umeclidinium/Vilanterol
- —Trial running · NCT06474039
Trough FEV1, change
- fluticasone furoate/umeclidinium/vilanterol
- 0.1 vs -0.0vs BUD/FORNCT02345161
14 other results
- 0.1 vs 0.1 NCT02729051
- 0.1 vs -0.1 NCT02345161
- 0.1 vs -0.0 NCT02164513
- 0.1 vs 0.0 NCT03474081
- 0.0 vs -0.0 NCT03478696
- 0.0 vs -0.0 NCT03478683
- 0.1 vs 0.0 NCT03474081
- 0.0 vs -0.0 NCT03478696
- 0.0 vs -0.0 NCT03478683
- 0.1 vs -0.0 NCT03474081
- 0.0 vs -0.0 NCT03478696
- 0.0 vs -0.0 NCT03478683
- 0.0 vs -0.0 NCT03478696
- 0.0 vs 0.0 NCT03478683
- Umeclidinium/Vilanterol
- 0.2 vs 0.1vs TIONCT01777334
3 other results
- 0.1 vs -0.0 NCT01899742
- 0.2 vs 0.2 NCT02487446
- 0.2 vs 0.2 NCT02487446
SGRQ total, change
- fluticasone furoate/umeclidinium/vilanterol
- -6.6 vs -4.3vs BUD/FORNCT02345161
3 other results
- -4.6 vs -1.9 NCT02345161
- -5.5 vs -3.7 NCT02164513
- -5.8 vs -4.9 NCT02729051
- Umeclidinium/Vilanterol
- —Trial running · NCT06474039
TDI focal score
- fluticasone furoate/umeclidinium/vilanterol
- 2.3 vs 1.7vs BUD/FORNCT02345161
1 other result
- 1.7 vs 1.4 NCT02345161
- Umeclidinium/Vilanterol
- —Trial running · NCT06474039
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. fluticasone furoate/umeclidinium/vilanterol: 4 of 4 rows · Umeclidinium/Vilanterol: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | fluticasone furoate/umeclidinium/vilanterol | Umeclidinium/Vilanterol |
|---|---|---|
| Dropout rate | 10.5%FF/UMEC/VIa NCT02164513 · Phase 3 show 9 more results—100/62.5/25 NCT02164513 · Phase 3 4.9%100/62.5/25 µg NCT02345161 · Phase 3 6.1% NCT04923347 · Phase 4 · registry result, not featured evidence 9.5% NCT05535972 · Phase 4 · registry result, not featured evidence 3%100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI NCT03467425 · Phase 4 · registry result, not featured evidence 4.3%100/62.5/25 mcg NCT03474081 · Phase 4 · registry result, not featured evidence 4.6%100/62.5/25 mcg NCT03478696 · Phase 4 · registry result, not featured evidence 3.6%100/62.5/25 mcg NCT03478683 · Phase 4 · registry result, not featured evidence 5.7%100/62.5/25 NCT02729051 · Phase 3 · registry result, not featured evidence | 11.7%62.5/25 µgb NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 5 more results—62.5/25 µg once daily NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 — NCT02487446 · Phase 3 · registry result, not featured evidence —27.5/12.5 Bid NCT02487498 · Phase 3 · registry result, not featured evidence 6.9%62.5/25 µg NCT01899742 · Phase 3 · registry result, not featured evidence —62.5/25 µg NCT02014480 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | 3.9%FF/UMEC/VIa NCT02164513 · Phase 3 show 9 more results—100/62.5/25 NCT02164513 · Phase 3 1.8%100/62.5/25 µg NCT02345161 · Phase 3 — NCT04923347 · Phase 4 · registry result, not featured evidence 1.3% NCT05535972 · Phase 4 · registry result, not featured evidence 0.6%100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI NCT03467425 · Phase 4 · registry result, not featured evidence 1.5%100/62.5/25 mcg NCT03474081 · Phase 4 · registry result, not featured evidence 0.3%100/62.5/25 mcg NCT03478696 · Phase 4 · registry result, not featured evidence 1.4%100/62.5/25 mcg NCT03478683 · Phase 4 · registry result, not featured evidence 4%100/62.5/25 NCT02729051 · Phase 3 · registry result, not featured evidence | 4%62.5/25 µgb NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 5 more results—62.5/25 µg once daily NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 — NCT02487446 · Phase 3 · registry result, not featured evidence —27.5/12.5 Bid NCT02487498 · Phase 3 · registry result, not featured evidence 2%62.5/25 µg NCT01899742 · Phase 3 · registry result, not featured evidence —62.5/25 µg NCT02014480 · Phase 3 · registry result, not featured evidence |
| Serious AEs | —FF/UMEC/VIa NCT02164513 · Phase 3 show 9 more results21.6%100/62.5/25 NCT02164513 · Phase 3 6.7%100/62.5/25 µg NCT02345161 · Phase 3 0.4% NCT04923347 · Phase 4 · registry result, not featured evidence 4.1% NCT05535972 · Phase 4 · registry result, not featured evidence 7.4%100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI NCT03467425 · Phase 4 · registry result, not featured evidence 3.3%100/62.5/25 mcg NCT03474081 · Phase 4 · registry result, not featured evidence 4.4%100/62.5/25 mcg NCT03478696 · Phase 4 · registry result, not featured evidence 8%100/62.5/25 mcg NCT03478683 · Phase 4 · registry result, not featured evidence 10.4%100/62.5/25 NCT02729051 · Phase 3 · registry result, not featured evidence | 3.5%62.5/25 µgb NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 5 more results1.7%62.5/25 µg once daily NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 3.8% NCT02487446 · Phase 3 · registry result, not featured evidence 5%27.5/12.5 Bid NCT02487498 · Phase 3 · registry result, not featured evidence 2.8%62.5/25 µg NCT01899742 · Phase 3 · registry result, not featured evidence 0.5%62.5/25 µg NCT02014480 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | 100/62.5/25a viral upper respiratory tract infection 12.5% upper respiratory tract infection 7.2% headache 5.6% NCT02164513 · Phase 3 show 8 more resultsdysphonia 0.4% abdominal discomfort 0.2% abdominal pain upper 0.2% NCT05535972 · Phase 4 · registry result, not featured evidence 100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI dyspnoea 2.1% NCT03467425 · Phase 4 · registry result, not featured evidence 100/62.5/25 mcg headache 4.5% nasopharyngitis 4% NCT03474081 · Phase 4 · registry result, not featured evidence 100/62.5/25 mcg headache 3.6% nasopharyngitis 1.9% NCT03478696 · Phase 4 · registry result, not featured evidence 100/62.5/25 viral upper respiratory tract infection 10.6% headache 6.1% upper respiratory tract infection 3.4% NCT02729051 · Phase 3 · registry result, not featured evidence | 62.5/25 µgb headache 8.8% nasopharyngitis 6.2% cough 2.9% NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 5 more results62.5/25 µg once daily nasopharyngitis 4% headache 3.5% NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 chronic obstructive pulmonary disease 10.6% nasopharyngitis 5.6% oropharyngeal pain 2.9% NCT02487446 · Phase 3 · registry result, not featured evidence 27.5/12.5 Bid chronic obstructive pulmonary disease 14.8% bronchitis 3.3% sinusitis 1.8% NCT02487498 · Phase 3 · registry result, not featured evidence 62.5/25 µg nasopharyngitis 7.3% headache 6.5% NCT01899742 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
- bPopulation comparability has not been reviewed for 4 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
fluticasone furoate/umeclidinium/vilanterol
show 2 more results
show 3 more results
show 1 more result
show 1 more result
show 17 more results
show 1 more result
show 1 more result
+ 7 further endpoints in the CSV export.
Umeclidinium/Vilanterol
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fluticasone furoate/umeclidinium/vilanterol's landscape · Umeclidinium/Vilanterol's landscape